Amer Zeidan: Can Early Blood Count Changes Predict Imetelstat Response in Lower Risk MDS?
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Cancer Journal, adding:
“Our newest paper on association between early neutropenia and thrombocytopenia with subsequent clinical response to imetelstat in lower risk MDS.”
Title: Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Authors: Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker and Rami S. Komrokji
Stay updated on all scientific advances Hemostasis Today.
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera
-
Sep 5, 2026, 05:48Punit Mathur: From Leg Pain to Life-Threatening Pulmonary Embolism
-
Sep 5, 2026, 05:44Patrick Stonich: Identifying Missed Signs of Postoperative Pulmonary Embolism in Medical Record Reviews
-
Sep 5, 2026, 05:38Tom Van den Hoek: Warburg Effect Mimicking Refractory Shock in Cancer-Associated PE
-
Sep 5, 2026, 05:11Shinya Goto: Targeted Thrombolysis for High Risk Pulmonary Embolism
-
Sep 5, 2026, 04:56Opportunities for the Next Generation of Hematologists – American Society of Hematology